Business Wire

NY-ESTÉE-LAUDER

25.6.2020 14:02:08 CEST | Business Wire | Press release

Share
The Estée Lauder Companies Announces the Promotion of Jane Hertzmark Hudis To Executive Group President

This week, The Estée Lauder Companies (NYSE:EL) announced that Jane Hertzmark Hudis has been promoted to Executive Group President, effective July 1, 2020. She will continue to report directly to Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies (ELC), with brand portfolio oversight of Estée Lauder, La Mer, Bobbi Brown, AERIN, Origins, Aveda, Bumble and bumble, Dr. Jart+ and Do The Right Thing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005430/en/

As one of the most accomplished, visionary executives in the prestige beauty industry, Jane is highly regarded for her track record of building and leading global brands. In her elevated role, Jane’s portfolio reflects several of the highest growth areas of the Company, including skin care and driving success across China and APAC, as well as with Chinese consumers around the world.

“This well-deserved promotion recognizes Jane’s exceptional leadership across the Company,” said Mr. Freda. “Throughout her career, she has made a significant impact driving brand-building expertise, spearheading the elevation of marketing and talent, and leading her portfolio of brands to achieve outstanding broad-based growth across categories, regions and channels. I am grateful to Jane for all that she has done to drive the Company’s success and as an advisor to me, and I know that she will continue to lead and inspire us to even greater heights in the future.”

As an enterprise-wide leader, most recently as Group President, Jane has been the Company’s top skin care strategist, helping to drive expertise in this critical area. Today, Estée Lauder is the number one brand in skin care globally, and La Mer is the number one brand in luxury skin care globally. A champion of the Company’s hero franchise strategy, she has driven innovation and built iconic franchises including Estée Lauder’s Advanced Night Repair and La Mer’s Créme de La Mer. The outstanding results of her brands are a testament to her strategic vision, expertise in local relevance, exceptional talent for driving innovation in product and consumer marketing, and digital communication.

A passionate advocate of leadership development and inclusion and diversity throughout her career, Jane co-founded ELC’s Women’s Leadership Network in 2017 to inspire and engage women across the organization, helping them become exceptional leaders and mentors. In partnership with co-executive sponsors Tracey T. Travis, Executive Vice President and Chief Financial Officer and Sara E. Moss, Vice Chairman, Jane has expanded the Women’s Leadership Network to over 2,000 members globally, with local chapters in France and the United Kingdom.

Jane’s expertise has been widely recognized by many best-in-class organizations. She serves on the Board of Tiffany & Co. and as a Director of the Fashion Institute of Technology (FIT) Foundation, as well as on the Advisory Board of the Breast Cancer Research Foundation.

Prior to her promotion to Group President in 2016, Jane served for seven years as Global Brand President, Estée Lauder, where she led the brand’s modernization and digital evolution to attract a new generation of global consumers. She solidified Estée Lauder's position as a global leader in high-performance prestige skin care and makeup, growing net sales by more than 40 percent and establishing it as the number one brand in its prestige distribution in Asia. Preceding her leadership of Estée Lauder, Jane served in a number of key leadership roles at the Company, including President of Origins and BeautyBank, a brand innovation think tank she founded in 2003.

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.

ELC-C
ELC-B
ELC-L

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release

€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This

Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release

~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye